Y-mAbs Therapeutics is parting ways with its chief commercial officer and putting a new hire in charge of the cancer drug Danyelza. The biotech made the changes, which include “a small ...

After hours: February 3 at 4:25:18 PM EST Loading Chart for YMAB ...

Late this week, a quartet of companies—IGM Biosciences, Y-mAbs Therapeutics, Passage Bio and Shoreline Biosciences—each revealed plans to cut jobs as they rework their respective pipelines and ...

Y-mAbs Therapeutics, Inc. has presented preclinical and translational pharmacokinetic data of their GD2-SADA bispecific fusion protein at the 2025 Society of Nuclear Medicine & Molecular Imaging ...

Platform can deliver a variety of payloads and could potentially be developed against multiple tumor targets, as well as for radiopharmaceutical purposes. Y-mAbs is currently evaluating its SADA PRIT ...

LifeArc will provide expertise in humanization of monoclonal antibodies (MAbs) to target key drivers of conditions identified by Cleveland Clinic, including cancer and complement-mediated diseases.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Michael and Andrew Buxton’s MAB Corp wants to swap out office space for residential in one of the towers at the NewQuay precinct in Melbourne’s Docklands. The developer is one of two partnering with ...